You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR mutant lung cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant

Completed
  • The Primary Study Metric is Progression-free Survival (PFS)
    • (no location specified)
    Jun 28, 2023

    NSCLC Trial in Boston (Osimertinib)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Boston, Massachusetts
    • +1 more
    Sep 28, 2022

    Lung Cancer Metastatic, EGFR Gene Mutation Trial in San Francisco (Osimertinib, Alisertib)

    Recruiting
    • Lung Cancer Metastatic
    • EGFR Gene Mutation
    • San Francisco, California
      University of California, San Francisco
    Aug 10, 2022

    NSCLC Trial in Boston, Durham (Osimertinib, Selumetinib)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • Boston, Massachusetts
    • +3 more
    Aug 1, 2022

    Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Orange,

    Not yet recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • +8 more
    • Orange, California
    • +2 more
    Aug 10, 2022

    Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

    Recruiting
    • Non-small Cell Lung Cancer
      • Guanzhou, China
        Sun Yat-sen University Cancer Center
      Aug 11, 2023

      NSCLC Trial in Singapore (Oral S-1 + Oral Osimertinib)

      Not yet recruiting
      • NSCLC
      • Oral S-1 + Oral Osimertinib
      • Singapore, Singapore
        National Cancer Center Singapore
      Mar 6, 2023

      Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in

      Not yet recruiting
      • Metastatic Lung Non-Small Cell Carcinoma
      • +2 more
      • Cetuximab
      • +2 more
      • Sacramento, California
        University of California Davis Comprehensive Cancer Center
      Oct 2, 2023

      EGF-R Positive NSCLC, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion Trial in Bogotá (Stereotactic Body Radiation Therapy

      Not yet recruiting
      • EGF-R Positive Non-Small Cell Lung Cancer
      • +4 more
      • Stereotactic Body Radiation Therapy SBRT
      • Bogotá, Colombia
        CTIC - Centro de Tratamiento e Investigación Sobre Cáncer Luis C
      Aug 16, 2023

      IASLC Grading System as a Predictor for EGFR-TKI Therapy

      Completed
      • Lung Cancer
      • IASLC grading system
      • Shanghai, Please Select, China
        Chaoqiang Deng
      Nov 9, 2023

      EGFR Mutant Advanced NSCLC Trial (BBT-207)

      Not yet recruiting
      • EGFR Mutant Advanced Non-Small Cell Lung Cancer
      • (no location specified)
      Jun 16, 2023

      NSCLC Trial (Almonertinib Envafolimab)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • Almonertinib Envafolimab
      • (no location specified)
      Sep 10, 2022

      NSCLC Metastatic Trial in Seoul (Lazertinib, Tepotinib)

      Not yet recruiting
      • Non-Small Cell Lung Cancer Metastatic
      • Seoul, Gangnam-gu, Korea, Republic of
        Samsung Medical Center
      Oct 27, 2023

      EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

      Recruiting
      • EGFR Exon 20 Mutation
      • +3 more
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 12, 2022

      Non Small Cell Lung Cancer Trial in Seoul (Lazertinib+Pemetrexed+Carboplatin, Lazertinib)

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • Seoul, Korea, Republic of
        Yonsei University Health System, Severance Hospital
      Aug 31, 2023

      Lung Cancer Trial in Guangzhou (Aumolertinib)

      Not yet recruiting
      • Lung Cancer
      • Guangzhou, Guangdong, China
        The First Affiliated Hospital of Guangzhou Medical University
      Jul 7, 2023

      NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • (no location specified)
      May 23, 2023

      EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

      Recruiting
      • Non-small Cell Lung Cancer
        • Changsha, Hunan, China
          Yongchang Zhang
        Feb 28, 2022

        Metastatic NSCLC Trial in United States (Dacomitinib, Osimertinib)

        Active, not recruiting
        • Metastatic Non-small Cell Lung Cancer
        • Basking Ridge, New Jersey
        • +6 more
        Dec 28, 2021

        NSCLC, EGFR Activating Mutation Trial in Guangzhou (Sintilimab, Carboplatin, Nab paclitaxel)

        Recruiting
        • Non-small Cell Lung Cancer
        • EGFR Activating Mutation
        • Sintilimab
        • +2 more
        • Guangzhou, Guangdong, China
          Guangdong Lung Cancer Institute, Guangdong Provincial People's H
        Aug 8, 2022

        EGFR Mutant Advanced NSCLC Trial (JIN-A02)

        Not yet recruiting
        • EGFR Mutant Advanced Non-small Cell Lung Cancer
        • (no location specified)
        Jul 8, 2022

        NSCLC Trial in Jinan (DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin))

        Recruiting
        • Non-small Cell Lung Cancer
        • DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin)
        • Jinan, Shandong, China
          Shandong Cancer Hospital (Shandong Provincial Institute of Cance
        Jun 22, 2023

        Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial (Poziotinib

        Not yet recruiting
        • Metastatic Lung Non-Small Cell Carcinoma
        • +3 more
        • Poziotinib Hydrochloride
        • 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE
        • (no location specified)
        Jul 18, 2022

        NSCLC Trial (Furmonertinib)

        Not yet recruiting
        • Non-Small Cell Lung Cancer
        • (no location specified)
        Aug 10, 2023

        Lung Cancer Stage IV, EGFR T790M Trial in Seoul (Lazertinib)

        Not yet recruiting
        • Lung Cancer Stage IV
        • EGFR T790M
        • Seoul, MA, Korea, Republic of
          Samsung Medical Center
        Jan 26, 2023